Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606920 | 0.84 | NPC1 (0.49) | NPC1RAB9AALDH1A1LMNAMAPK1 | |
| SCHEMBL4342386 | 0.84 | ALDH1A1 (0.49) | PTPN1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8089488 | 0.79 | GRM4 (0.43) | NPC1RAB9AALDH1A1LMNAMAPK1 | |
| SCHEMBL31423422 | 0.78 | PLOD2 (0.55) | PLOD2PTPN1NPC1RAB9ALMNA | |
| SCHEMBL20491280 | 0.77 | CES2 (0.49) | NPC1RAB9AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1873597 | 0.77 | PLOD2 (0.46) | PLOD2ALDH1A1LMNAMAPK1CASP3 | |
| SCHEMBL2074862 | 0.75 | PLOD2 (0.60) | PLOD2PTPN1NPC1RAB9AHTR7 | |
| SCHEMBL8088532 | 0.75 | GSK3B (0.57) | PLOD2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8081324 | 0.75 | NR4A2 (0.57) | NPC1RAB9AALDH1A1LMNAMAPK1 | |
| SCHEMBL9244575 | 0.74 | ADRB2 (0.49) | PLOD2PTPN1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5968938-A | Piperazine oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | PLOD2 4312/4885PTPN1 1694/4885NPC1 710/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | PLOD2 4495/4885PTPN1 3411/4885NPC1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.